CN114807038B - 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 - Google Patents
一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 Download PDFInfo
- Publication number
- CN114807038B CN114807038B CN202210126912.8A CN202210126912A CN114807038B CN 114807038 B CN114807038 B CN 114807038B CN 202210126912 A CN202210126912 A CN 202210126912A CN 114807038 B CN114807038 B CN 114807038B
- Authority
- CN
- China
- Prior art keywords
- tumor
- lymphoma
- cell
- mouse
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010025323 Lymphomas Diseases 0.000 title claims abstract description 57
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 57
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 36
- 210000004027 cell Anatomy 0.000 claims abstract description 98
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 71
- 238000010171 animal model Methods 0.000 claims abstract description 7
- 238000004321 preservation Methods 0.000 claims abstract description 7
- 210000001519 tissue Anatomy 0.000 claims abstract description 7
- 206010054949 Metaplasia Diseases 0.000 claims abstract description 6
- 230000015689 metaplastic ossification Effects 0.000 claims abstract description 6
- 210000002220 organoid Anatomy 0.000 claims abstract description 6
- 230000007246 mechanism Effects 0.000 claims abstract description 4
- 238000010276 construction Methods 0.000 claims abstract description 3
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000011580 nude mouse model Methods 0.000 abstract description 8
- 238000002054 transplantation Methods 0.000 abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 230000012010 growth Effects 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001788 irregular Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710088083 Glomulin Proteins 0.000 description 3
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 3
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 3
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 3
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 3
- 102000013127 Vimentin Human genes 0.000 description 3
- 108010065472 Vimentin Proteins 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000005222 synovial tissue Anatomy 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 210000005048 vimentin Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 101100285899 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SSE2 gene Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100293737 Mus musculus Nde1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100027287 Serpin H1 Human genes 0.000 description 1
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000018212 fibroblastic neoplasm Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 230000000998 lymphohematopoietic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开了一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF‑KT及其应用,该细胞株来源于人淋巴瘤细胞裸鼠移植瘤模型中的瘤体组织微环境,其细胞名称为小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF‑KT,保藏编号为CCTCC NO:C2021105,保藏日期:2021年12月09日,保藏单位:中国典型培养物保藏中心。该细胞株为国内外首次建立的源自移植瘤体的淋巴瘤相关小鼠成纤维细胞肿瘤细胞株,可在构建小鼠成纤维细胞肿瘤动物模型、淋巴瘤微环境模型、3D肿瘤培养体系和类器官体系模型以及淋巴瘤细胞所导致的成纤维细胞肿瘤化生的机制模型等的应用。
Description
技术领域
本发明属于生物医学技术领域,具体的说,是一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用。
背景技术
淋巴瘤是一组起源于淋巴造血系统的恶性肿瘤,属于常见肿瘤之一,近年来发病率逐渐上升,主要表现为无痛性淋巴结肿大,肝脾肿大,全身各组织器官均可受累,伴发热、盗汗、消瘦、瘙痒等全身症状。根据瘤细胞分为霍奇金淋巴瘤(Hodgkin lymphoma,简称HL)和非霍奇金淋巴瘤(non Hodgkin lymphoma ,简称NHL)两类。
肿瘤微环境,即肿瘤细胞产生和生活的内环境,其中不仅包括了肿瘤细胞本身,还有其周围的成纤维细胞、免疫和炎性细胞、胶质细胞等各种细胞,同时也包括附近区域内的细胞间质、微血管以及浸润在其中的生物分子。由于肿瘤微环境与肿瘤细胞所处的内外环境密切相关,因此,肿瘤微环境对肿瘤的发生、发展和转归也具有重要的影响。
肿瘤微环境中,癌相关成纤维细胞(cancer-associated fibroblasts, CAFs)是活化的成纤维细胞,是构成实体肿瘤微环境的主要细胞成分;CAFs通过分泌纤连蛋白和胶原蛋白等细胞外基质蛋白,重塑肿瘤细胞外基质微环境;CAFs还可与肿瘤细胞以及肿瘤微环境中的其它细胞直接或通过分泌生物活性分子间接相互作用;从而促进肿瘤生长、转移、诱导血管生成,甚至参与诱导肿瘤耐药,影响患者预后。CAFs是一种具有高度异质性的细胞,可来源于多种前体细胞,包括:骨髓间充质干细胞、组织中固有成纤维细胞、星形细胞、上皮细胞间质转化、内皮细胞间质转化、纤维细胞和其他细胞,如周细胞、平滑肌细胞、脂肪细胞和肿瘤干细胞等。由于不同来源的CAFs在肿瘤的进展中起不同的作用,因此构建不同来源的CAFs细胞有助于深入探索肿瘤病理。
王翠等在“股骨头坏死(ONFH)患者滑膜组织来源的类成纤维细胞对人Burkitt淋巴瘤(BL)Raji细胞增值的影响”,《复旦学报(医学版)》,2015 Jan.,42(1),77-83,中通过分离ONFH患者滑膜组织来源的类成纤维细胞,将其与Raji细胞共同培养,发现在类成纤维细胞的刺激下,通过调节Raji细胞中P53、P21及CD9的表达可显著促进Raji细胞的增殖,表明ONFH可能会进一步促进淋巴瘤细胞的增殖。因此,在临床上使用高剂量糖皮质激素治疗BL时需特别注意并发的ONFH对肿瘤的潜在促进作用,尤其对于那些易于并发ONFH的患者。ONFH患者滑膜组织中培养的类成纤维细胞属于炎性反应活化的成纤维细胞,虽然细胞来源与CAF相似但并不属于肿瘤微环境,未被肿瘤细胞“驯化”。
发明内容
本发明的目的在于提供小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT,是一株瘤体来源小鼠淋巴瘤相关成纤维细胞肿瘤细胞株,该细胞株为国内外首次建立的源自移植瘤体淋巴瘤相关小鼠成纤维细胞肿瘤细胞株。为此,本发明还提供了该细胞株在构建小鼠成纤维细胞肿瘤动物模型、淋巴瘤微环境模型、3D肿瘤培养体系和类器官体系模型、淋巴瘤细胞所导致的成纤维细胞肿瘤化生的机制模型、淋巴瘤相关成纤维细胞肿瘤与淋巴瘤微环境的关系模型、淋巴瘤相关成纤维细胞肿瘤与淋巴瘤化疗耐药的关系模型中的应用。
本发明通过下述技术方案实现:一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT,来源于人淋巴瘤细胞裸鼠移植瘤模型中的瘤体组织微环境,其细胞名称为小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT,保藏编号为CCTCC NO:C2021105,保藏日期:2021年12月09日,保藏单位:中国典型培养物保藏中心,保存单位地址为中国湖北省武汉市武汉大学。
所述小鼠成纤维细胞肿瘤细胞株来源于人间变性大细胞淋巴瘤细胞Karpas299裸鼠移植瘤模型,取自移植瘤瘤体,是一株淋巴瘤相关小鼠成纤维细胞肿瘤细胞株。该细胞株的原代细胞来源于人间变性大细胞淋巴瘤细胞株接种于裸鼠裸区皮下所形成的移植瘤;取肿块剪碎成组织块,体外接种培养,去除悬浮细胞,获得贴壁生长细胞;细胞传代10代后,形态相对均一,以长梭形为主,可见不规则三角形或多角形,胞浆可见突起,核浆比倒置,核仁清晰,无接触抑制,可交叉重叠生长,细胞密集时成团聚集;在体外稳定无限传代,具高致瘤性;命名为小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT。
本发明涉及的小鼠成纤维细胞肿瘤细胞株HXLyAF-KT具有以下生物学特性:
经转录组测序分析,为小鼠来源细胞。
经western bloting检测结果显示:该细胞高表达S100A4、α-SMA、Vimentin、HSP47、FAP、β-catenin、PDGFR-α和PDGFR-β,为成纤维细胞来源肿瘤。
HXLyAF-KT细胞在RPMI 1640完全培养基中贴壁生长,以长梭形为主,可见不规则三角形或多角形,胞浆可见突起,体外培养生长良好,按2.5×105/55cm2密度接种,3~4天传代一次,已经体外连续培养超过6个月,传代超过60代,群体倍增超过135代,连续传代过程中细胞形态和增殖动力学稳定、遗传学特征稳定,状态良好;经液氮或超低温冻存、复苏后性状不变,为一株永生化细胞株。
采用台盼蓝染色细胞计数法绘制HXLyAF-KT细胞的生长曲线,计算细胞倍增时间为31~34小时,增殖速率稳定,可见分裂相,分裂后细胞仍贴壁;证实细胞株具有增殖动力学稳定性。
采用PI染色法和染色体核型分析证实,HXLyAF-KT细胞为混合克隆细胞,DNA倍体异常。
本发明还提供了将上述小鼠成纤维细胞肿瘤细胞株HXLyAF-KT在构建小鼠成纤维细胞肿瘤动物模型中的应用,在构建3D肿瘤培养体系和类器官体系模型中的应用,在构建淋巴瘤相关成纤维细胞肿瘤与淋巴瘤微环境的关系模型中的应用。
本发明还提供了该小鼠成纤维细胞肿瘤细胞株在构建小鼠成纤维细胞肿瘤动物模型中的应用,在构建淋巴瘤微环境模型中的应用,在构建3D肿瘤培养体系和类器官体系模型中的应用,在构建淋巴瘤细胞所导致的成纤维细胞肿瘤化生的机制模型中的应用,在构建淋巴瘤相关成纤维细胞肿瘤与淋巴瘤微环境的关系模型中的应用,在构建淋巴瘤相关成纤维细胞肿瘤与淋巴瘤化疗耐药的关系模型中的应用。为淋巴瘤治疗提供新的思路和靶点,为探索靶向CAFs的肿瘤治疗新方法提供研究平台。
本发明与现有技术相比,具有以下优点及有益效果:
(1)本发明为目前首次建立的移植瘤瘤体来源淋巴瘤相关小鼠成纤维细胞肿瘤细胞株HXLyAF-KT,该细胞株具有高致瘤性,可用于建立小鼠成纤维细胞肿瘤动物模型,并构建3D肿瘤培养体系和类器官体系。将HXLyAF-KT细胞接种裸鼠,接种后3天即可在皮下触及肿块,5天后肿块迅速生长,致瘤率100%,且成瘤细胞与体外培养的HXLyAF-KT细胞来源一致。
(2)本发明可将小鼠成纤维细胞肿瘤细胞株HXLyAF-KT应用于淋巴瘤微环境的研究中,获取体外建立淋巴瘤微环境的研究平台,获取淋巴瘤细胞导致成纤维细胞肿瘤化生的相关数据,获取淋巴瘤相关成纤维细胞肿瘤与淋巴瘤微环境的关系的相关数据,为其在治疗淋巴瘤过程中获取淋巴瘤化疗耐药等相关数据。
附图说明
图1为倒置相差显微镜下HXLyAF-KT细胞观察图(×200)。
图2 为透视电镜下下HXLyAF-KT细胞超微结构图(×6000)。
图3为HXLyAF-KT细胞生长曲线图。
图4为HXLyAF-KT细胞周期图。
图5为Western blotting检测HXLyAF-KT细胞S100A4、α-SMA、Vimentin、HSP47、FAP、β-catenin、PDGFR-α和PDGFR-β表达图。
图6 为HXLyAF-KT细胞裸鼠皮下肿瘤形成实验图。
图7为HXLyAF-KT细胞裸鼠皮下肿瘤生长曲线图。
具体实施方式
下面将本发明的发明目的、技术方案和有益效果作进一步详细的说明。
应该指出,以下详细说明都是示例性的,旨在对所要求的本发明提供进一步的说明,除非另有说明,本文使用的所有技术和科学术语具有与本发明所属技术领域的普通技术人员通常理解的相同含义。其中,移植瘤体或移植瘤瘤体是指肿瘤细胞皮下接种部位生长的肿瘤块。
实施例1:
本实施例涉及小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT的分离和建株,具体步骤如下:
(1)将处于对数生长期的人间变性大细胞淋巴瘤细胞Karpas299按3×106个/100µl/只,接种于雌性 Balb/c (nu/nu) 小鼠(8周龄,体重20~22g)裸区皮下;隔日观察接种部位肿瘤生成情况,接种21天后肿块体积约428.5 mm3,取瘤块制成细胞悬液;重悬在含10%胎牛血清(Thermo公司)的RPMI 1640培养基(Gibco公司)中,置37℃、饱和湿度、5% CO2培养箱培养。6天后可见贴壁细胞生长,去除上清和悬浮细胞,每2~3天换液,30天后培养皿中悬浮细胞基本去除,贴壁细胞多形性,呈簇状生长,用0.25%胰酶-EDTA(Hyclone公司)消化传代,此后每10~14天传代一次,接种85天后细胞形态较之前均一,细胞增殖加快, 110天后细胞增殖明显快,细胞以长梭形、不规则三角形或多角形为主。
(2)HXLyAF-KT细胞传代时的初始密度为2.5×105个/55cm2,当细胞增殖到80%融合时1:5到1:10传代。
(3)HXLyAF-KT细胞冻存前48小时换液,使细胞处于对数生长期,计数细胞,无菌条件下,将细胞转入离心管,1200转/分离心5分钟,弃上清,加入冻存液,调整细胞浓度为1~3×106个/ml,充分混匀,移入无菌冻存管,4℃,30min; -20℃,60min;-80℃过夜,次日移入液氮。
(4)复苏时,从液氮中取出冻存管,迅速置于37℃温水中,待冻存物融化后,将细胞悬液移入加入5ml RPMI 1640培养基的离心管中,轻柔混匀,1200转/分,离心5分钟,弃上清,细胞沉淀中加入RPMI 1640完全培养基,混匀,转移入培养皿,置37℃、饱和湿度、5% CO2培养箱培养。
(5)HXLyAF-KT细胞经反复如上述步骤(3)和步骤(4)冻存复苏,稳定生长,不影响细胞的生物学特征,显微镜下见细胞形态比较均一,梭形、不规则三角形或多角形,贴壁生长,细胞倍增时间维持在31~34小时。
上述步骤中,RPMI 1640完全培养基的配方采用90% RPMI 1640培养基和10%胎牛血清。冻存液的配方采用45% RPMI 1640培养基,50%胎牛血清和5% DMSO(Sigma公司)。
实施例2:
本实施例是针对实施例1所述细胞株HXLyAF-KT进行的生长和生物学特性鉴定,具体操作如下:
(1)细胞形态学观察:
取对数生长期的HXLyAF-KT细胞于倒置显微镜下观察活细胞形态,如图1所示,细胞贴壁生长,以长梭形为主,可见不规则三角形或多角形,胞浆可见突起,核浆比倒置,核仁清晰,无接触抑制,可交叉重叠生长,细胞密集时成团聚集;3%戊二醛预固定,1%四氧化锇再固定,醋酸铀和枸橼酸铅染色JEM-1400FLASH透视电镜下观察细胞超微结构,如图2所示,可见细胞核呈不规则形,有切迹,核膜清晰,核仁明显,核凹,胞浆粗面内质网增多,游离核糖体丰富,胞浆可见空泡和内质网、线粒体等细胞器。
(2)倍增时间测定:
离心收集对数生长期的细胞,调整细胞浓度为2×103个/3.8cm2,接种于12孔板中,置37℃、5%CO2、21%O2培养箱中培养12天,每天用台盼蓝染色计数细胞。以时间为横坐标,细胞数为纵坐标,绘制细胞生长曲线,计算细胞倍增时间为31~34小时,可见细胞株经反复传代,群体倍增次数到200多代,仍然保持增殖动力学稳定性。
(3)PI染色法监测细胞周期:
收获1×106个细胞,4℃预冷PBS洗2次,4℃ 75% 乙醇固定过夜,4℃ PBS洗2次,PI室温避光染色10min,流式细胞仪检测细胞周期,结果如图3所示,HXLyAF-KT细胞为混合克隆细胞,DNA倍体异常。
(4)转录组测序检测证实HXLyAF-KT细胞细胞为小鼠来源细胞。
(5) western bloting检测结果显示:该细胞高表达S100A4、α-SMA、Vimentin、HSP47、FAP、β-catenin、PDGFR-α和PDGFR-β,为成纤维细胞来源肿瘤,如图4所示。
以上结果显示,淋巴瘤细胞可以导致成纤维细胞肿瘤化生。
实施例3:
本实施例涉及将实施例1所述细胞株HXLyAF-KT用于构建小鼠成纤维细胞肿瘤动物模型,采用裸鼠成瘤实验,具体实验过程如下:
将处于对数生长期的HXLyAF-KT细胞按3×106个/200µl/只,接种于3只雌性Balb/c (nu/nu) 小鼠(5周龄,体重15~19g)裸区皮下;隔日观察接种部位肿瘤生成情况,结果如图6和图7所示,接种2天后可在裸鼠皮下触及米粒大小肿块,接种5天后肿瘤迅速生长,隔天测量肿块大小,可见肿块体积从第5天的120 mm3生长到第25天的2338 mm3,25天后取瘤块,留取部分组织行多聚甲醛固定,石蜡包埋,切片,染色。
以上所述,仅是本发明的较佳实施例,并非对本发明做任何形式上的限制,凡是依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化,均落入本发明的保护范围之内。
Claims (7)
1.一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT,其特征在于:来源于人淋巴瘤细胞裸鼠移植瘤模型中的瘤体组织微环境,其细胞名称为小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT,保藏编号为CCTCC NO:C2021105,保藏日期:2021年12月09日,保藏单位:中国典型培养物保藏中心。
2.将权利要求1所述小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT在构建小鼠成纤维细胞肿瘤动物模型中的应用。
3.将权利要求1所述小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT在构建淋巴瘤微环境模型中的应用。
4.将权利要求1所述小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT在构建3D肿瘤培养体系和类器官体系模型中的应用。
5.将权利要求1所述小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT在构建淋巴瘤细胞所导致的成纤维细胞肿瘤化生的机制模型中的应用。
6.将权利要求1所述小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT在构建淋巴瘤相关成纤维细胞肿瘤与淋巴瘤微环境的关系模型中的应用。
7.将权利要求1所述小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT在构建淋巴瘤相关成纤维细胞肿瘤与淋巴瘤化疗耐药的关系模型中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210126912.8A CN114807038B (zh) | 2022-02-11 | 2022-02-11 | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210126912.8A CN114807038B (zh) | 2022-02-11 | 2022-02-11 | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114807038A CN114807038A (zh) | 2022-07-29 |
CN114807038B true CN114807038B (zh) | 2023-11-10 |
Family
ID=82527605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210126912.8A Active CN114807038B (zh) | 2022-02-11 | 2022-02-11 | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114807038B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114703138B (zh) * | 2022-02-09 | 2023-07-07 | 四川大学华西第二医院 | 一种淋巴结来源淋巴瘤相关成纤维细胞肿瘤细胞株及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009312532A1 (en) * | 2008-11-06 | 2010-05-14 | Ichnos Sciences SA | Treatment with anti-alpha2 integrin antibodies |
JP2014000038A (ja) * | 2012-06-19 | 2014-01-09 | Nagoya Univ | 悪性リンパ腫のインビトロ腫瘍細胞モデル及びその利用 |
CN103609519A (zh) * | 2013-11-12 | 2014-03-05 | 邓飞 | Balb/c小鼠间变性大细胞淋巴瘤动物模型的构建方法 |
CA3099260A1 (en) * | 2017-05-09 | 2018-11-15 | Scholar Rock, Inc. | Lrrc33 inhibitors and use thereof |
CN110291080A (zh) * | 2016-12-21 | 2019-09-27 | 安塞塔制药公司 | 布鲁顿酪氨酸激酶的咪唑并吡嗪抑制剂 |
CN114703138A (zh) * | 2022-02-09 | 2022-07-05 | 四川大学华西第二医院 | 一种淋巴结来源淋巴瘤相关成纤维细胞肿瘤细胞株及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130344490A1 (en) * | 2012-04-27 | 2013-12-26 | Min Peter Kim | Neoplastic cells grown on decellularized biomatrix |
-
2022
- 2022-02-11 CN CN202210126912.8A patent/CN114807038B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009312532A1 (en) * | 2008-11-06 | 2010-05-14 | Ichnos Sciences SA | Treatment with anti-alpha2 integrin antibodies |
JP2014000038A (ja) * | 2012-06-19 | 2014-01-09 | Nagoya Univ | 悪性リンパ腫のインビトロ腫瘍細胞モデル及びその利用 |
CN103609519A (zh) * | 2013-11-12 | 2014-03-05 | 邓飞 | Balb/c小鼠间变性大细胞淋巴瘤动物模型的构建方法 |
CN110291080A (zh) * | 2016-12-21 | 2019-09-27 | 安塞塔制药公司 | 布鲁顿酪氨酸激酶的咪唑并吡嗪抑制剂 |
CA3099260A1 (en) * | 2017-05-09 | 2018-11-15 | Scholar Rock, Inc. | Lrrc33 inhibitors and use thereof |
CN114703138A (zh) * | 2022-02-09 | 2022-07-05 | 四川大学华西第二医院 | 一种淋巴结来源淋巴瘤相关成纤维细胞肿瘤细胞株及其应用 |
Non-Patent Citations (3)
Title |
---|
ALK plus Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment;Chioureas, Dimitrios等;CANCERS;第14卷(第12期);全文 * |
Klotho调控IGF-1R信号通路在非霍奇金淋巴瘤中的作用及机制研究;周香香;中国博士学位论文全文数据库(电子期刊)医药卫生科技辑;E072-48 * |
骨原发性恶性纤维组织细胞瘤21例光镜、电镜、组化和免疫组化研究;向理科等;重庆医科大学学报(第3期);228-230 * |
Also Published As
Publication number | Publication date |
---|---|
CN114807038A (zh) | 2022-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Puck et al. | Clonal growth in vitro of human cells with fibroblastic morphology: comparison of growth and genetic characteristics of single epithelioid and fibroblast-like cells from a variety of human organs | |
TASHJIAN JR et al. | Establishment of clonal strains of rat pituitary tumor cells that secrete growth hormone | |
Engelholm et al. | Disaggregation of human solid tumours by combined mechanical and enzymatic methods | |
US20100129330A1 (en) | Adipocytic differentiated adipose derived adult stem cells and uses thereof | |
TW200411059A (en) | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use | |
CN114703138B (zh) | 一种淋巴结来源淋巴瘤相关成纤维细胞肿瘤细胞株及其应用 | |
CN114807038B (zh) | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 | |
CN111084905A (zh) | 利用羊膜间充质干细胞制备人工羊膜的方法 | |
Gingrich et al. | Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1) | |
CN110699324B (zh) | 一种小鼠成纤维细胞肿瘤细胞株及其应用 | |
CN103421740B (zh) | 一种人骨髓间充质干细胞体外培养扩增方法 | |
CN114457017B (zh) | 一种小鼠成纤维细胞肿瘤细胞株HXLyAF-KBM及其应用 | |
CN107446891B (zh) | 一种以自身脐带间充质干细胞作为基质细胞扩增人类脐带血造血干细胞的方法 | |
CN104745530A (zh) | 一种人肝细胞癌细胞系及其建立方法和应用 | |
CN107864627A (zh) | 包含粘附基质细胞的方法和组合物 | |
Bruland et al. | The use of multicellular spheroids in establishing human sarcoma cell lines in vitro | |
van der Bosch et al. | Growth characteristics of primary tissue cultures from heterotransplanted human colorectal carcinomas in serum-free medium | |
CN102154208A (zh) | Cd133+脑胶质瘤干细胞抗原负载树突状细胞的制法及其应用 | |
CN105087466A (zh) | 诱导脐带间充质干细胞向角膜上皮细胞分化的培养基和方法 | |
CN107460170B (zh) | 人垂体腺瘤细胞系的建立及其应用 | |
RU2628092C1 (ru) | Способ получения МСК-ассоциированных недифференцированных гемопоэтических клеток-предшественников с фенотипов CD34+/CD133+ | |
CN105695412B (zh) | 一种人肺腺癌细胞株ha109及其建立方法 | |
CN114672457A (zh) | 来源于肿瘤组织的具有肿瘤特异性杀伤效果的t淋巴细胞及其制备方法和细胞制剂 | |
CN113817777B (zh) | 来源于人的先天性巨大黑痣良性肿瘤细胞系及其构建方法 | |
CN110468100A (zh) | 培养基及骨髓间充质干细胞的成骨诱导方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |